Anticoagulant Utilization Pattern

Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist

NCT00075985 ·Status: COMPLETED

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

NCT02061748 ·Status: COMPLETED

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

NCT04878497 ·Status: UNKNOWN

Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

NCT04435769 ·Status: COMPLETED

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

NCT03254134 ·Status: COMPLETED

Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation

NCT03666962 ·Status: UNKNOWN

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

NCT02067182 ·Status: COMPLETED ·Phase: PHASE4

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

NCT02470767 ·Status: COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150 ·Status: UNKNOWN

Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients

NCT00356759 ·Status: COMPLETED ·Phase: PHASE2

Medical Need of OAC Reversal

NCT03254147 ·Status: COMPLETED

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808 ·Status: COMPLETED

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers

NCT02559232 ·Status: COMPLETED

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

NCT00448214 ·Status: COMPLETED ·Phase: PHASE2

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

NCT02769078 ·Status: COMPLETED

Early Identification of Warfarin Maintenance Dosage

NCT01178034 ·Status: COMPLETED ·Phase: PHASE3

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

NCT04249401 ·Status: COMPLETED

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)

NCT02906527 ·Status: UNKNOWN

Αdherence and Persistence to Oral Anticoagulation in ΑF Patients With Previous Ischemic Stroke

NCT03463421 ·Status: UNKNOWN

Warfarin - How Good Are we at Maintaining Target Range ?

NCT01081327 ·Status: COMPLETED

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

NCT02591732 ·Status: COMPLETED

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction

NCT03359876 ·Status: COMPLETED

A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

NCT00787150 ·Status: COMPLETED ·Phase: PHASE2

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

NCT03189069 ·Status: COMPLETED

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767 ·Status: COMPLETED ·Phase: PHASE3